SCHEMBL5914261

SCHEMBL5914261

CN(c1ccnc(NC2CCN(C(=O)O)C(C(C)(C)C)C2)n1)c1cc(-c2ccccc2)cc(=O)n1C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ MAPK8 P45983 3/20 0.33
▸ MAPK9 P45984 3/20 0.33
▸ JUN P05412 2/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ HDAC8 Q9BY41 2/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ MAPK1 P28482 4/20 0.32
▸ CDK2 P24941 3/20 0.32
▸ CCNA2 P20248 2/20 0.32
▸ MAPK3 P27361 2/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ MAPK14 Q16539 2/20 0.31
▸ KDR P35968 2/20 0.31
▸ AURKA O14965 1/20 0.31
▸ TTK P33981 1/20 0.31
▸ AURKB Q96GD4 1/20 0.31
▸ INCENP Q9NQS7 1/20 0.31
▸ FGFR1 P11362 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5341690 0.83 USP30 (0.48) USP30MAPK1MAPK14
SCHEMBL5914092 0.82 KDR (0.33) USP30CYP3A4MAPK8MAPK9JUN
SCHEMBL5341694 0.77 MAPK14 (0.43) USP30MAPK8MAPK9JUNMAPK10
SCHEMBL4107974 0.74 KDM4E (0.39) HDAC8HDAC6MAPK1
SCHEMBL5914255 0.73 SCD (0.36) MAPK14KDRAURKA
SCHEMBL5914262 0.72 MAPK14 (0.37) MAPK1MAPK14AURKA
SCHEMBL5267139 0.70 ACACB (0.41) USP30CYP3A4
SCHEMBL5914172 0.70 MAPK14 (0.35) USP30MAPK14
SCHEMBL5317262 0.68 MAPK8 (0.39) CYP3A4MAPK8MAPK9JUNMAPK10
SCHEMBL5315409 0.68 KDM4E (0.39) MAPK1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060069110-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2006-03-30 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069110-A1 Substituted heterocyclic compounds and methods of use MAPT, MYLK2, IAPP USP30 3267/4885CYP3A4 1290/4885MAPK8 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback